Protocol and Personnel: Standardization of Serum Therapy Across Institutional Settings?

The standardization of serum therapy across institutional settings was a sustained effort spanning the late 1970s through the early 1990s, driven by the need to measure treatment outcomes consistently when serum therapy became the first viable systemic alternative to the limited azo drugs. Until the Halloway-Umezaki method proved clinically effective in trials, the administration of animal-derived serum therapies remained a localized practice, varying widely between hospitals in dosage, donor selection, patient preparation, and follow-up measurement.

The International Serum Registry, established in 1975 to coordinate data across participating nations, could not generate meaningful treatment comparisons until hospitals submitted data in identical formats. The first major effort toward uniform administration came from a working committee convened by the Geneva Sanitary Bureau in 1978, which examined protocols from forty-three hospitals across sixteen countries. The committee's report, Toward Convergence in Serum Administration, issued in 1979, identified more than two hundred documented variations in single-dose preparation, patient fasting requirements, injection depth and location, observation periods, and measurement of immune response.

The technical problem was substantial. Serum potency varied with the age and immunization status of donor animals, the purification methods available at each production facility, and the storage conditions in each hospital. A dose prepared at a specialized serum farm in Copenhagen might contain double the quantity of functional antibodies as an equivalent volume from a facility in Tokyo, yet both claimed the same nominal strength. Without standardized dosing, clinicians could not determine whether poor outcomes reflected inadequate treatment, biological variation in the patient, or simply a weak batch of serum.

The institutional friction was deeper. Hospitals in the asepsis maximalism tradition—particularly those built or rebuilt after the Bacillary Congress of Geneva in 1952—had developed elaborate protocols for patient isolation, preparation, and discharge that integrated infection control with serum therapy administration. Altering these routines to match a Geneva standard risked disrupting containment measures that staff had calibrated over decades. Surgeons trained in one tradition viewed the methods of another as reckless; microbiologists trained in another saw them as redundant.

The resolution came through a combination of technical standards and institutional incentive. Beginning in 1981, the International Serum Registry began accepting submissions only from hospitals meeting baseline requirements for serum storage, potency verification, and patient follow-up documentation. By 1985, participation had become essential to accessing donor serum allocations in years of shortage. The Geneva Sanitary Bureau published successive editions of Standard Protocols for Serum Therapy Administration in 1983, 1987, and 1991, each version incorporating field experience and narrowing acceptable variation.

The Archives of the Institute for the History of Bacteriology: Umezaki Papers contain extensive records of the standardization process, including Dorothy Umezaki's correspondence with hospital committees, her notes on site visits to institutions resisting uniform protocols, and drafts of technical language designed to accommodate regional differences while maintaining comparability. Umezaki's position was that perfect uniformity was neither possible nor desirable—different patient populations, different disease presentations, and different institutional architectures justified some variation—but that hospitals must document and justify their departures from published standards rather than following undocumented local practice.

By 1992, approximately eighty percent of hospitals in developed nations reporting to the International Serum Registry used protocols within the boundaries established by the 1991 Geneva standard. In developing countries and in nations with limited serum production capacity, variation remained wider, but even in those settings the existence of a published standard meant that departures were identified as such rather than viewed as normal practice.

The standardization process left a permanent mark on how serum therapy outcomes were measured. Because statistical comparison required uniform data collection, hospitals adopted standardized forms for patient intake, dosing records, adverse reactions, and follow-up survival measurement. These forms, preserved in institutional archives across Europe, North America, and Japan, document not just the science of serum therapy but the mundane administrative labor through which asepsis maximalism and passive immunotherapy were integrated into routine institutional practice. A clerk recording a patient's serum batch number and injection time was participating in a global standardization effort that made bacterial infection treatment comparable and, in principle, improvable.

The effort was not complete consensus. Some clinicians continued to argue that premature standardization had locked hospitals into protocols designed for the disease presentations and animal stock available in Geneva in 1991, foreclosing the possibility of discovering better methods adapted to local conditions. The standardization committees' own records from the late 1980s show persistent disagreement over whether dosing should be scaled to patient weight, body surface area, or infection severity, and whether follow-up measurement should track bacterial clearance, toxin neutralization, or patient survival. These debates were never resolved; they were managed through the publication of multiple acceptable protocols and the requirement that hospitals choose one and stick to it consistently.